A Phase 2 interventional study of Telmisartan in HIV Infection, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-04.
Sponsored by University of California, Los Angeles · Phase 2, Interventional, and Treatment
This is a research study to see whether fat accumulation either under the skin or in the body's organs, for example, the liver, improves in men and women who take a drug called telmisartan. The investigators will be looking at how the amount of fat in the body changes when HIV-positive persons on effective anti-HIV therapy take telmisartan. The investigators will be using a CT scan to make this comparison. Telmisartan is not an HIV medication. It is a medication used to treat blood pressure, but has been shown to decrease fat in the organs in people both with and without high blood pressure. The study involves 8 visits over a period of about 24 weeks.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 35 is below the median of 120 across 4,201 interventional studies indexed under Infections.
Browse Infections studies →University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Telmisartan 40mg po daily for 24 weeks
Drug: Telmisartan
Also known as: Micardis
Median Change in Visceral Adipose Tissue (VAT) Volume
VAT volume was quantified at each timepoint by L4-L5 single slice computed tomography
Time frame: Baseline and 24 weeks
Subjects were recruited between May and October 2010 at the UCLA CARE Center.
| Milestone | Telmisartan |
|---|---|
| Started | 36 |
| Completed | 35 |
| Not completed | 1 |
VAT volume was quantified at each timepoint by L4-L5 single slice computed tomography
| cm^2 | Telmisartan |
|---|---|
| Median Change in Visceral Adipose Tissue (VAT) Volume | -4.6 (-29.5 to 31.2) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Telmisartan | — | 0/35 (0%) | 0/35 (0%) |
| Age, Categorical(Participants) | Telmisartan |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 36 |
| >=65 years | 0 |
| Age, Continuous(years) | Telmisartan |
|---|---|
| Mean | 49 ± 7.4 |
| Sex: Female, Male(Participants) | Telmisartan |
|---|---|
| Female | 16 |
| Male | 20 |
| Region of Enrollment(participants) | Telmisartan |
|---|---|
| United States | 36 |
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of California, Los Angeles